Sun Pharmaceuticals Industries Ltd Performance
Open
1531
Traded Value (Cr)
270.33 Cr
Prev. Close
1520.15
VWAP
1508.52
Volume
38,46,327
Face Value
1
Sun Pharmaceuticals Industries Ltd Fundamentals
Sun Pharmaceuticals Industries Ltd F&O
Sun Pharmaceuticals Industries Ltd Financials
Resistance and Support
₹1,489.37
PIVOT
 Resistance | |
|---|---|
| First Resistance | ₹1,499.383 |
| Second Resistance | ₹1,513.017 |
| Third Resistance | ₹1,523.033 |
 Support | |
|---|---|
| First Resistance | ₹1,475.733 |
| Second Resistance | ₹1,465.717 |
| Third Resistance | ₹1,452.083 |
| RSI | 26.500 |
| MACD | -51.483 |
| ADX | 27.795 |
| CCI | -80.312 |
Delivery and Volume
About Sun Pharmaceuticals Industries Ltd
Sun Pharmaceutical Industries Ltd. (Sun Pharma), which generates global sales of more than US$ 5.1 billion, is the fourth-largest specialty generic pharmaceutical firm in the world. With the help of more than 40 production facilities, we supply more than 100 nations with high-quality, reasonably priced medications that are dependable among patients and medical experts. In Vapi, Gujarat, Dilip Shanghvi founded Sun Pharmaceuticals in 1983 with five mental drug products. Cardiology and gastrointestinal products first became available in 1987 and 1989, respectively. Currently, it is India's top-selling prescription drug and a market leader in cardiology, gastroenterology, orthopedics, diabetology, dermatology, urology, vitamins, minerals, and nutrients. Sun Pharma became the biggest pharmaceutical firm in India, the biggest Indian pharmaceutical business in the US, and the fourth-largest specialty generic company in the world after purchasing Ranbaxy in 2014. The United States and other markets outside of India account for more than 72% of Sun Pharma's sales. The US is the company's single-largest market, contributing around 30% of total sales, with formulations or final dosage forms accounting for 93% of sales. 44 locations worldwide, including those in Europe, Asia, Africa, Australia, and the US, are used for manufacturing. The firm sells a wide range of generic medications in the US, and it has a healthy pipeline of products awaiting FDA clearance. In 1994, Sun Pharma went public on the stock market in a 55-fold oversubscribed offering. The company's majority ownership remains with the original family. It was 1994 when Sun Pharma went public. To generate money and become a publicly listed corporation, a firm must first offer its shares to the general public. This is known as an IPO. Investors were able to become shareholders in Sun Pharma by purchasing shares of the business at the 1994 IPO. It was priced at Rs 150 to issue, and it was listed for about Rs 220. The stock price dropped from its listing price within a month of the IPO, by roughly 20%. Sun Pharmaceutical Industries Ltd., is a large-cap company in the pharmaceuticals sector with a market capitalization of Rs. 259,572.05 billion. Pharmaceuticals and Other Operating Revenue are among Sun Pharmaceutical Industries Ltd.'s primary product/revenue segments for the fiscal year ending March 31, 2022. Consolidated Total Income for the three months ending March 31, 2023, was Rs 11,303.95 crore, down 97% from the previous quarter's total income of Rs 11,414.85 crore and up 18.24% from the same period last year's total income of Rs 9,560.35 crore. In the most recent quarter, the company generated a net profit after tax of Rs 2,016.78 billion. The top executives of the firm include Mr. Israel Makov, Mr. Dilip S. Shanghvi, Dr. Uday Baldota, Mr. Abhay Gandhi, Mr. Kirti Ganorkar, Mr. Kalyanasundaram Subramanian, Mr. Sailesh T. Desai, Dr. Pawan Goenka, Mr. Rama Bijapurkar, Mr. Sudhir V. Valia, Mr. Gautam Doshi, Mr. C. S. The company's auditors are S R B C & Co. LLP. As of March 31, 2023, the corporation has 239.93 billion shares outstanding. Ranbaxy Laboratories Limited (2014): Sun Pharmaceutical purchased Ranbaxy Laboratories Limited, a renowned Indian pharmaceutical business, in 2014, in one of the most important acquisitions in the pharmaceutical sector. Sun Pharma was able to dramatically increase its market share and product portfolio thanks to the $3.2 billion transaction. AstraZeneca (2016): To develop and market certain products in China, Sun Pharmaceutical and the international pharmaceutical giant AstraZeneca established a joint venture in 2016. The partnership made use of AstraZeneca's global reach and Sun Pharma's manufacturing capabilities. Pola Pharma Inc. (2021): Sun Pharmaceutical stated in January 2021 that it has agreed to buy the Japanese pharmaceutical firm Pola Pharma Inc. for about JPY 2,800 million. Sun Pharma's position in the Japanese pharmaceutical industry was to be strengthened by this tactical action. The share price of Sun Pharmaceutical Industries Ltd. is a crucial sign of how investors feel about the business. Several variables, including the company's financial performance, the state of the global economy, and market sentiment, have an impact on the share price. Over the past several years, Sun Pharmaceutical Industries Ltd.'s share price has been on the rise, indicating the company's solid financial performance and growth potential. You can check the live price of Sun Pharmaceutical Industries Ltd from the above part.Company Overview
Sun Pharmaceutical Industries Ltd - History and Expansion
IPO of Sun Pharmaceutical Industries Ltd
About Company
Group companies
Sun Pharmaceutical Industries Ltd Share Price
Managing Director
Dilip S Shanghvi
Founded
1993
NSE Symbol
SUNPHARMA
Sun Pharmaceuticals Industries Ltd Management
| Name | Designation |
|---|---|
| Dilip S Shanghvi | Managing Director |
| Sudhir V Valia | Non-Exec & Non-Independent Dir |
| Sailesh T Desai | Whole-time Director |
| Gautam Doshi | Non-Exec. & Independent Dir. |
| Pawan Goenka | Lead Independent Director |
| Rama Bijapurkar | Independent Director |
| Anoop Deshpande | Company Sec. & Compli. Officer |
| Sanjay K Asher | Independent Director |
| Rolf Hoffmann | Independent Director |
| Aalok Shanghvi | Whole Time Director |